Jiuzhou Pharmaceutical(SH:603456) Xin Lang Cai Jing·2025-10-14 02:09Core Viewpoint - Jiuzhou Pharmaceutical experienced a stock price increase of 5.28%, reaching 20.32 CNY per share, with a trading volume of 228 million CNY and a total market capitalization of 18.074 billion CNY as of October 14 [1] Company Overview - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. was established on July 13, 1998, and went public on October 10, 2014. The company is located at No. 99, Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province. Its main business involves the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Shareholder Information - Among the top ten circulating shareholders of Jiuzhou Pharmaceutical, a fund under Huabao Fund holds a significant position. The Huabao CSI Medical ETF (512170) increased its holdings by 467,700 shares in the second quarter, bringing its total to 17.7854 million shares, which accounts for 2% of the circulating shares. The estimated floating profit from this investment is approximately 18.1411 million CNY [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a current scale of 26.147 billion CNY. Year-to-date returns are 15.61%, ranking 3206 out of 4220 in its category; the one-year return is 10.99%, ranking 3266 out of 3857; and since inception, the return is 13.29% [2]